IDENTIFYING BIOMARKERS FOR IMMUNOTHERAPY USING SPATIAL BIOLOGY
With
Associate Professor Arutha Kulasinghe
Chair in Spatial Medicine and Principal Research Fellow,
Frazer Institute, University of Queensland, &
Founding Scientific Director,
Queensland Spatial Biology Centre,
Wesley Research Institute,
Queensland, Australia
RESEARCHER PROFILE
Filmed in Sydney, Australia | October 2026
Associate Professor Arutha Kulasinghe is a Principal Research Fellow at The University of Queensland’s Frazer Institute, where he leads the Clinical-oMx Lab. He holds the inaugural Brazil Family Chair in Spatial Medicine and is the founding Scientific Director of the Queensland Spatial Biology Centre at the Wesley Research Institute. He completed his PhD at Queensland University of Technology.
A/Prof Kulasinghe is a pioneer of spatial biology in the Asia-Pacific region and among the first to apply spatial transcriptomics, proteomics and interactomics there. He combines these technologies in an integrated multi-omics approach to understand the biology that drives disease. His research centres on immuno-oncology in lung, skin, and head and neck cancers, with a particular focus on the tumour microenvironment and on finding biomarkers that predict which patients will respond to immunotherapy. He also develops liquid biopsy approaches for lung and head and neck cancer, and has led tissue-atlas studies of infectious diseases, including COVID-19 and pandemic influenza.
He has authored more than 120 peer-reviewed publications, in journals including Nature Genetics, Nature Communications, The Lancet Microbe and the Journal of Clinical Oncology. His honours include Cure Cancer’s Researcher of the Year (2023), The Australian’s Top Innovators (2024), a Research Australia UNSW Frontiers Award (2026) and InDaily Queensland’s 40 Under 40 (2026). He has also been named on The Courier-Mail’s Queensland Power Lists for technology and medicine (2026). His work is supported by the MRFF, NHMRC, US Department of Defense, Cancer Australia, Cure Cancer, industry, and hospital and philanthropic partners.
- Source: Supplied
- Media Access Credit: Research Australia 2025-26 Health and Medical Research Awards
https://orcid.org/0000-0003-3224-7350
-
Better biomarkers for predicting the incidence of having atherosclerosis and heart attack
Assoc Prof Bursill is a vascular biologist with interests and expertise in vascular inflammation, atherosclerosis and angiogenesis. She completed her PhD at The University of Adelaide in lipid metabolism then headed to Oxford University for five years to undergo a postdoctoral post in the Departments of Cardiovascular Medicine and Pathology. Her postdoctoral time triggered her interest in the mechanisms that cause atherosclerosis and in particular the role of small inflammatory proteins called chemokines.
-
Neuroscience, neuropharmacology and exercise science
Dr Jacob Thorstensen is an early-career Assistant Professor in Neuroscience and Physiology in the Faculty of Health Sciences & Medicine at Bond University. He is also an honorary research fellow in The School of Biomedical Sciences at The University of Queensland. His work has unveiled several new neuroscientific mechanisms which have future applications for movement disorders.
-
Unnecessary tests and treatments in low value critical care
Dr Gerben Keijzers is a Senior Staff Specialist Emergency Physician at the Gold Coast University Hospital Emergency Department. His research focus includes low-value care, which is in the area of unnecessary tests and treatments with minimal benefits. Dr Keijzers has contributed to over 100 publications and more than 20 grant applications. Through his involvement in multi-site collaborative research projects, he encourages critical thinking and curiosity among clinical staff, striving to enhance both patient care and the efficiency of healthcare resources.
